CorMedix Ownership
| CRMD Stock | USD 10.94 0.08 0.74% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 61.5 M | Current Value 69 M | Avarage Shares Outstanding 19.3 M | Quarterly Volatility 19.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. CorMedix Stock Ownership Analysis
About 34.0% of the company shares are held by institutions such as insurance companies. The company last dividend was issued on the 26th of March 2019. CorMedix had 1:5 split on the 26th of March 2019. CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey. Cormedix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people. For more info on CorMedix please contact Joseph MBA at 908 517 9500 or go to https://www.cormedix.com.CorMedix Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CorMedix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CorMedix backward and forwards among themselves. CorMedix's institutional investor refers to the entity that pools money to purchase CorMedix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2025-03-31 | 371.1 K | Susquehanna International Group, Llp | 2025-03-31 | 322.4 K | Amvescap Plc. | 2025-03-31 | 289.1 K | Nuveen, Llc | 2025-03-31 | 274.7 K | Swedbank Ab | 2025-06-30 | 250 K | Exoduspoint Capital Management, Lp | 2025-03-31 | 231.5 K | D. E. Shaw & Co Lp | 2025-03-31 | 230.6 K | Marshall Wace Asset Management Ltd | 2025-03-31 | 230.5 K | Goldman Sachs Group Inc | 2025-03-31 | 179.8 K | Blackrock Inc | 2025-03-31 | 4.7 M | Vanguard Group Inc | 2025-03-31 | 3.6 M |
CorMedix Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CorMedix insiders, such as employees or executives, is commonly permitted as long as it does not rely on CorMedix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CorMedix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CorMedix Outstanding Bonds
CorMedix issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CorMedix uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CorMedix bonds can be classified according to their maturity, which is the date when CorMedix has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
CorMedix Corporate Filings
| 30th of June 2025 Other Reports | ViewVerify | |
8K | 25th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 12th of May 2025 Other Reports | ViewVerify | |
| 28th of April 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CorMedix is a strong investment it is important to analyze CorMedix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CorMedix's future performance. For an informed investment choice regarding CorMedix Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.25 | Revenue Per Share | Quarterly Revenue Growth (0.47) | Return On Assets | Return On Equity |
The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CorMedix's value and its price as these two are different measures arrived at by different means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.